Show More 1 Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia In the article that accompanies this editorial, Capdevila et al 20 now demonstrate the efficacy of ...

Anaplastic thyroid carcinoma is one of the most aggressive and deadly cancers in humans and accounts for one to two cases per million persons annually. The rarity of this malignancy and the rapidity ...

Please provide your email address to receive an email when new articles are posted on . “Anaplastic thyroid cancer patients with prior histories of other cancers have similar survival outcomes as ...

The study covered in this summary was published on Research Square as a preprint and has not yet been peer reviewed. Anaplastic thyroid cancer is a rare thyroid malignancy; disease-specific mortality ...

Two prospective trials of immunotherapy in thyroid cancer, one of them negative, provided support for precision-medicine approaches that include immunotherapy. The studies were reported simultaneously ...

HOUSTON ― Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival ...

In patients with metastatic anaplastic thyroid cancer who have progressed on chemotherapy — who have a poor prognosis —a new combination of nonchemotherapy drugs shows promise. The combination of the ...

Scientists from Wuhan University and affiliated organizations have published findings from their investigation into the role of Yes-associated protein (YAP), which is a critical effector of the Hippo ...

Please provide your email address to receive an email when new articles are posted on . The triplet combination of vemurafenib/cobimetinib/atezolizumab showed ...

Anaplastic thyroid cancer (ATC), a rare yet highly aggressive malignancy, continues to represent a major clinical challenge. A recent review published in Genes & Diseases offers a comprehensive ...